TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of chronic ITP defined by: Failure to find other causes of thrombocytopenia; Platelet count ≤ 150 x 10\^9/L over 6 months or response to a previous treatment with subsequent decrease in platelet count even if duration of chronic ITP is less than 6 months~* Platelet counts ≤ 20 x 10\^9/L~Key Exclusion Criteria:~* Planned splenectomy throughout the study period~* Treatment with IVIG or anti-D immunoglobulin within 3 weeks prior to screening~* Treatment with immunosuppressive or other immunomodulatory drugs within 3 weeks prior to screening~* Treatment with intravenous steroids within 10 days prior to screening~* Change of oral steroid treatment within 15 days prior to screening~* Patients with known or suspected hypersensitivity to immunoglobulins or previous severe side effects to immunoglobulin therapy~* Abnormal results in the following laboratory parameters: Hemoglobin \< 10 g/dL; Total bilirubin \> 1.5 x upper normal limit; ALAT \> 2.5 x upper normal limit; ASAT \> 2.5 x upper normal limit; Creatinine \> 1.5 x upper normal limit; Urea \> 1.5 x upper normal limit~* Positive direct Coombs test~* Patients with one of the following concomitant diseases Clinical active SLE Known or suspected HIV infection Acute hepatitis Clinically active chronic hepatitis Lymphoproliferative disease Heart failure Grade III or IV according to the New York Heart Association classification~* Any other concomitant disease that has influence on the clotting system (i.e. hemophilia)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- IgPro10 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-positive individuals aged 20 year or more, and~* Those who had completed at least a primary series of HAV vaccination (i.e. two doses of HAVRIX 1440, 6-12 months apart; or two doses of Vaqta 50U, 6-18 months apart), and~* Those who failed to achieve serological response at least 4 weeks after the last dose of primary HAV vaccination.~Exclusion Criteria:~* Patients who have acute illness or acute hepatitis A related symptoms (fever, malaise, nausea, vomiting, abdominal discomfort, and jaundice) within 30 days.~* Patients who have positive anti-HAV IgM within 30 days.~* Patients who were taking immunosuppressant or steroid.~* Patients who were allergic to HAV vaccine.~* Incompetent or unconsented patients.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1-dose group (Type: ACTIVE_COMPARATOR): Provide 1 booster dose of HAV vaccine (Vaqta Injectable Product) to those who failed to response after primary HAV vaccination.
- 2-dose group (Type: EXPERIMENTAL): Provide 2 booster doses of HAV vaccine (Vaqta Injectable Product) to those who failed to response after primary HAV vaccination.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patients from study CACZ885G2305 or CACZ885G2301 who achieved an adapted ACR pediatric 30 response 15 days after their initial dose of canakinumab but clinically deteriorated afterwards or a minimum ACR Pediatric 30 response was not maintained after Day 15 and intervention is deemed necessary by the investigator, or Patients in study CACZ885G2301 who are not eligible to enter Part II (withdrawal part) because they were not able to meet the corticosteroid entry criteria , or Responder patients in Part I or Part II who had not flared when CACZ885G2301 was stopped, or CACZ885G2301 patients who were responders in Part I but experienced a flare in Part II.~* Treatment-naïve patients need to meet the following criteria:~  * Confirmed diagnosis of systemic juvenile idiopathic arthritis as per ILAR definition that must have occurred at least 2 months prior to enrollment with onset of disease \< 16 years of age~ * Male and female patients aged ≥ 2 to \< 20 years of age~ * Active disease at the time of enrollment defined as having 2 or more of the following:~    * Documented spiking, intermittent fever (body temperature \> 38°C) for at least 1 day during the screening period and within 1 week before first canakinumab dose~   * At least 2 joints with active arthritis~   * AND C-reactive protein (CRP) \> 30 mg/L (normal range \< 10 mg/L) Rash Serositis Lymphadenopathy Hepatosplenomegaly~ * Naïve to canakinumab~Other protocol-defined inclusion criteria may apply~Exclusion criteria:~* History of allergy or hypersensitivity to study drug~* With active or recurrent bacterial, fungal or viral infections at time of enrollment~Other protocol inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Canakinumab (Type: EXPERIMENTAL): Canakinumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Main Inclusion Criteria:~* FEV1/FVC ratio (post-bronchodilator) ≤70%~* FEV1 (post-bronchodilator) ≤50% of predicted~* Current smoker or ex-smoker~* Clinically stable COPD indicated by no exacerbation and no change in COPD treatment of within 4 weeks prior to baseline~* Availability of chest x-ray dated a maximum of 6 months prior to study baseline or a willingness to have a chest x-ray performed at baseline~Main Exclusion Criteria:~* COPD exacerbation indicated by a treatment with systemic glucocorticoids not stopped 4 weeks prior to baseline~* Lower respiratory tract infection not resolved 4 weeks prior to baseline~* Diagnosis of asthma and/or other relevant lung disease~* Known alpha-1-antitrypsin deficiency~* Need for long-term oxygen therapy defined as ≥16 hours/day

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Linaclotide in Patients With Chronic Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has completed a colonoscopy according to the AGA criteria, with no clinically significant findings~* Patient has successfully completed protocol procedures (with no clinically significant findings): physical exam, 12-lead ECG, or clinical laboratory tests~* Patient meets protocol criteria for CC: reports \< 3 bowel movements per week and reports straining, lumpy or hard stools, and/or sensation of incomplete evacuation during \> 25% of BMs~* Patient demonstrates continued chronic constipation through Pretreatment Period~* Patient is compliant with IVRS~Exclusion Criteria:~* Patient has history of loose or watery stools~* Patient has symptoms of or been diagnosed with Irritable Bowel Syndrome (IBS)~* Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility~* Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 145 μg linaclotide (Type: EXPERIMENTAL): None
- 290 μg linaclotide (Type: EXPERIMENTAL): None
- Matching Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* all cases above 18 years of age~Exclusion Criteria:

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): All patients receive the same treatment of MAb-425 +Iodine 125 in a total of three injections. The purpose of this protocol is to allow you to receive course(s) of 1251-MAB 425 until your brain tumor begins to grow, you develop side effects to the treatment, or your medical condition changes (ie: become affected with human immunodeficiency virus (HIV) or develop another cancer).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient Satisfaction and Sensory Attributes Allergic Rhinitis Nasal Spray

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Allergic Rhinitis patients (moderate-to-severe Seasonal Allergic Rhinitis or Perennial Allergic Rhinitis) with or without conjunctivitis who meet the following criteria will be offered the opportunity to participate in the study:~* Patients above 18 years old~* Fluent in English~* Patients initiated on RYALTRIS® or DYMISTA® nasal spray in the last 12 months and currently using treatment~* Willing and able to provide consent to participate~Exclusion Criteria:~* Have reported a loss of taste and/or smell related to COVID-19 (or other medical condition)~* Are employed by a pharmaceutical company (to avoid conflict of interest)~* Are employed by a vaccine company (to avoid conflict of interest)~* Do not have access to the internet (to ensure validity of the data)~* Are unable to read and understand English (to ensure validity of the data)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Patients on RYALTRIS (Type: None): Patients who are currently using RYALTRIS nasal spray.
- Patients on DYMISTA (Type: None): Patients who are currently using DYMISTA nasal spray.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cerebral Blood Perfusion Changes After General Anesthesia for Craniotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesia (ASA) physical status I or II~* Scheduled for selective supratentorial tumor removal surgery or major abdominal surgery.~Exclusion Criteria:~* Patients with evidence of systemic hypertension, intracranial hypertension, cerebrovascular diseases, other coexisting medical conditions likely to affect cerebral autoregulation.~* Preoperatively planned delayed tracheal extubation.~* Pregnant or nursing women

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Patients undergoing craniotomy (Type: EXPERIMENTAL): Patients undergoing craniotomy who are scheduled for selective supratentorial tumor removal surgery will be randomly chosen and recruited.~Transcranial Doppler (TCD) measures,jugular venous bulb catheterization, radial artery catheterization, and tumor removal surgery under general anesthesia will be performed.
- Patients undergoing abdominal surgery (Type: ACTIVE_COMPARATOR): Randomly chosen patients undergoing selective abdominal surgery. Transcranial Doppler (TCD) measures,radial artery catheterization, and major abdominal surgery under general anesthesia will be performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. 19 ≤ age ≤ 75~2. at Visit 1 1) BP: sitDBP ≥ 90mmHg 2) Cholesterol : LDL-C ≤ 250mg/dL, TG \< 400mg/dL~3. at Visit 2 : after TLC (after 4weeks) 1) BP: 80 mmHg ≤ sitDBP \< 110mmHg 2) Cholesterol : following risk category (Cardiovascular Risk category) A : CHD risk factor 0 - 1, 160mg/dL ≤ LDL-C ≤ 250mg/dL B①: CHD risk factor≥2 and 10 year risk \<10%, 160mg/dL ≤ LDL-C ≤ 250mg/dL B②: CHD risk factor≥2 and 10 year risk =10-20%, 130mg/dL ≤ LDL-C ≤ 250mg/dL C : CHD/CHD risk equivalents\* or 10 year risk\>20 ,100mg/dL ≤ LDL-C ≤ 250mg/dL 3) TG \< 400mg/dL 4. Patients understood the contents and purpose of this trial and signed informed consent form~Exclusion Criteria:~1. At Visit 1, BP difference SBP ≥20mmHg or DBP ≥10mmHg~2. Tolerance or Hypersensitivity Angiotensin II receptor blocker or HMG-CoA. reductase inhibitor, Calcium channel blocker(dihydropyridine) or Multi-drug allergy~3. Fibromyalgia, myopathy, rhabdomyolysis or acute myopathy or medical history of adverse effect to statin~4. CPK normal range ≥ 3times~5. Uncontrolled primary hypothyroidism(TSH normal range ≥ 2 times)~6. Renal disease or suspected renal disease (Scr ≥ 2mg/dL, AST or ALT≥2 times)~7. Active gout or hyperuricemia(at Visit 1, uric acid \> 9mg/dL)~8. IDDM or uncontrolled diabetes mellitus (HbA1c\>9%)~9. ventricular arrhythmia~10. medical history~    * severe cerebrovascular disease within 6 months (cerebral infarction, cerebral hemorrhage), hypertension~   * encephalopathy, transient cerebral ischemic attack(TIA)~   * severe heart disease(heart failure of NYHA class III-IV), valvular disease of heart or myocardial infarction and unstable angina~   * angioplasty or coronary artery bypass graft(CABG) surgery within 6months

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): HGP0904 + HGP0608 + HGP0816, once daily
- Active Comparator1 (Type: ACTIVE_COMPARATOR): HGP0904 placebo + HGP0608 + HGP0816, once daily
- Active Comparator2 (Type: ACTIVE_COMPARATOR): HGP0904 + HGP0608 + HGP0816 placebo, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 to ≤ 75 years of age~* Diagnosis of heterozygous familial hypercholesterolemia by having met the diagnostic criteria outlined by the Simon Broome Register Group (Scientific Steering Committee 1991)~* On an approved statin, with or without ezetimibe, with stable dose(s) for at least 4 weeks~* Fasting Low-Density Lipoprotein Cholesterol (LDL-C) ≥ 100 mg/dL~* Fasting triglycerides ≤ 400 mg/dL~Exclusion Criteria:~* Homozygous familial hypercholesterolemia~* Low-Density Lipoprotein (LDL) or plasma apheresis within 12 months prior to randomization~* New York Heart Association (NYHA) III or IV heart failure, or known left ventricular ejection fraction \< 30%~* Uncontrolled cardiac arrhythmia~* Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization~* Type 1 diabetes; newly diagnosed or poorly controlled type 2 diabetes (HbA1c \> 8.5%)~* Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every 4 weeks for 12 weeks.
- Evolocumab 350 mg (Type: EXPERIMENTAL): Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
- Evolocumab 420 mg (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A patient will be eligible for inclusion in this study only if ALL of the following criteria apply:~  1. Histologically confirmed cT2-T4a,N0-N+,M0 resectable esophageal squamous cell carcinoma~ 2. Eastern Cooperative Oncology Group (ECOG) performance status 0-1~ 3. Patients approve and sign the informed consent~Exclusion Criteria:~* 1. Patients with active autoimmune disease or history of autoimmune disease 2. Patients who have a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications 3. Subjects with a history of symptomatic interstitial lung disease 4. History of allergy to study drug components 5. Women must not be pregnant or breast-feeding 6. Men with female partners (WOCBP) that are not willing to use contraception 7. Patient has received prior chemotherapy, radiotherapy, target therapy and immune therapy for this malignancy or for any other past malignancy 8. Underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Arm 1:preoperative pembrolizumab with chemoradiotherapy group Participants will receive carboplatin (AUC=2) IV and paclitaxel (50mg/m²) IV on day 1,8,15,22,29. And radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week. Participants will also receive pembrolizumab (2mg/kg) IV on days 1 and 22. Surgery will be performed within 6 weeks after completion of preoperative therapy described above.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* No medical, psychiatric, or sleep disorders~* Ability to provide written informed consent~Exclusion Criteria:~* Lifetime history of night shift work~* Evidence of any sleep disorder~* Psychiatric or neurological disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Timolol on Refractive Outcomes in Eyes With Myopic Regression After LASIK: a Randomized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with myopic regression equal or more than 0.5 D with minimum age of 20 years,~* cylinder ≤ -1.00 D,~* corrected distance visual acuity (CDVA) of at least 20/40 were included.~Exclusion Criteria:~* Patients with a history of previous ocular surgery,~* keratoconus or any ectatic corneal disorder,~* keratoconus suspect by topography,~* preoperative corneal opacity,~* any corneal dystrophies,~* presence of pterygium,~* retinal disorders,~* collagen vascular disorders,~* diabetes mellitus,~* glaucoma,~* cataract,~* pregnancy,~* breast feeding~* systemic corticosteroid therapy were excluded.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): included patients who received artificial tear twice a day as control group.
- Timolol group (Type: EXPERIMENTAL): included the patients with myopic regression who received timolol 0.5% eye drop twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete